Just three months after completing its $1.8 billion takeover of Agios' oncology pipeline, Servier has reported positive results for lead drug Tibsovo that could expand the use of the drug in acute ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced ...

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade ...

French biopharma Servier has bought up Danish cancer biotech Symphogen as it looks to bolster its immuno-oncology pipeline. The deal, financial terms of which have not been made public, unusually, ...

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

International pharmaceutical group Servier has expanded its partnership with Google Cloud to accelerate the research and development (R&D) of pharmaceuticals. Servier and Google Cloud have entered ...

A Servier Pharmaceuticals drug acquired as part of a $1.8 billion deal has won an additional FDA approval as a treatment for a rare type of blood cancer carrying a specific mutation. The regulatory ...

Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China. The French pharma company has announced the opening of the Servier ...

SURESNES, France, Sept. 8, 2025 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement ...